1 295

Cited 16 times in

Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer

Authors
 Kang Su Cho  ;  Joong Shik Lee  ;  Nam Hoon Cho  ;  Kyeongmee Park  ;  Won Sik Ham  ;  Young Deuk Choi 
Citation
 PROSTATE, Vol.68(8) : 803-808, 2008 
Journal Title
 PROSTATE 
ISSN
 0270-4137 
Issue Date
2008
MeSH
Aged ; Aged, 80 and over ; Antineoplastic Agents, Hormonal/therapeutic use ; DNA Mutational Analysis ; Gene Amplification* ; Genes, erbB-2 ; Humans ; Male ; Middle Aged ; Mutation* ; Neoplasms, Hormone-Dependent/drug therapy ; Neoplasms, Hormone-Dependent/genetics* ; Prognosis ; Prostatic Neoplasms/diagnosis ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/genetics* ; Receptor, Epidermal Growth Factor/genetics*
Keywords
prostatic neoplasms ; genes ; erbB‐1 ; genes ; erbB‐2 mutation
Abstract
BACKGROUND: Amplification and mutation of the epidermal growth factor receptor (EGFR) and Her-2 genes were analyzed in both hormone sensitive and hormone refractory prostate cancer (HRPC). METHODS: Gene amplifications of EGFR and Her-2 were analyzed by fluorescence in situ hybridization (FISH) with direct sequencing. Studies were performed on a total of 10 patients; tissues were sampled at the time of initial diagnosis and after the conversion to HRPC (a total of 20 tissue samples). Direct sequencing was performed on exons 18-24 of EGFR and exons 19 and 20 of Her-2. Amplification and mutation were compared with clinicopathologic features. RESULTS: Gene amplification of EGFR was observed in 6 (30%) out of 20 samples. A total of six EGFR mutations in exons 18 and 19 were detected in three pairs of tissues (three patients). One patient, with hormone refractory status, had a novel deletion mutation in EGFR exon 19. EGFR mutations were associated with the acinar type of prostate cancer but were not associated with the ductal type. No significant correlation was found between mutation change and hormone sensitive or refractory status. However, the time to convert to HRPC was significantly shorter in the patients with a mutation in the EGFR gene (P = 0.017). There were no Her-2 gene amplifications or mutations found in any of the samples. CONCLUSIONS: EGFR gene mutation and amplification occurred frequently in advanced prostate cancer cases. EGFR mutations do not appear to play a significant role in the hormone refractory pathway but are associated with prognosis
Full Text
http://onlinelibrary.wiley.com/doi/10.1002/pros.20743/abstract
DOI
10.1002/pros.20743
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Lee, Joong Shik(이중식)
Cho, Kang Su(조강수) ORCID logo https://orcid.org/0000-0002-3500-8833
Cho, Nam Hoon(조남훈) ORCID logo https://orcid.org/0000-0002-0045-6441
Choi, Young Deuk(최영득) ORCID logo https://orcid.org/0000-0002-8545-5797
Ham, Won Sik(함원식) ORCID logo https://orcid.org/0000-0003-2246-8838
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/106462
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse